GETTING PRODUCTS TO PATIENTS

ABOUT US:

• New Rhein is a venture capital / growth stage fund manager focused on healthcare therapeutics and medical devices
• Our investment strategy focuses on proven molecules (e.g., molecules with proven mechanisms of action and/or established scientific rationale), used in new ways, such as new delivery forms or new indications
• In this way, New Rhein limits science-based risk and concentrates its focus on clinical and commercial execution
• We believe that “innovation drives greater risk-adjusted value than invention” and that major unmet medical needs can be addressed by existing solutions, improving health economic outcomes in doing so
• Prior investments have included medicines for  Alzheimer’s disease, ophthalmic disorders, respiratory disease, and molecular oncology diagnostics
• Our partners, associates, and advisors are knowledgeable former pharma industry executives with solid track records of operational, investment, and transactional experience
• New Rhein combines significant deal-making expertise with deep operating experience, allowing it to tailor the right deal for the right situation and support its portfolio companies to achieve maximum value for their products
• New Rhein is currently investing through its Fund 18